News

2024

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in Situ CAR T for Hematologic Malignances

IBJ Media's third annual Indiana 250 most influential leaders in Indiana

Secret Passageway Presentation

Philip Low to be honored by American Lung Association for cancer-fighting invention

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies

 

2023

Cancer Drug Discovered in Indiana to Power Indy Novartis Plant

Novartis in Indy

This Is Purdue - Full Interview with Professor Philip Low

Inside Indiana Business - Malaria

“FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer” Mar 4, 2023 ONCOLOGY Staff Oncology ONCOLOGY Vol 37, Issue 2 Volume 37 Issue 2 Pages: 53-54 (with my picture on the journal cover) Royalty income for Pluvicto

Video interview at AACR 2023

 

2022

Wlfi News: Purdue cancer research lab receives $8.5 million estate gift

Inside Indiana Business: Renowned Purdue Researcher Earns Another FDA Approval

U.S. Food & Drug Administration: FDA approves Pluvicto for metastatic castration-resistant prostate cancer

Purdue News: Award honors chemist for fight to beat cancer, save lives

Medical World News: Inside the Practice: Phillip Low, PhD, on the Development and Approval of Pafolacianine

 

2021

Inside Indiana Business: FDA Approves ‘Illuminating’ Drug for Spotting Cancer

U.S. Food & Drug Administration: FDA Approves Ctyalux(pafolacianine), a New Imaging Drug to Help Identify Ovarian Cancer Lesions

Novartis: FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Purdue News: FDA approves pioneering drug for ovarian cancer surgery

Purdue Center for Cancer Research: Member Feature

Globenewswire: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

CISION PR Newswire: On Target Laboratories Announces U.S. FDA Acceptance and Priority Review of New Drug Application for pafolacianine sodium injection for Identification of Ovarian Cancer During Surgery

 

2020

New Cancer Immunotherapy  https://www.purdue.edu/newsroom/releases/2020/Q4/new-cancer-immunotherapy-shows-great-promise-in-early-research.html

Inside Indiana Business  https://www.insideindianabusiness.com/story/42930780/purdue-startup-secures-major-funding-round

Endpoints – MPM backs $53M round for a bold concept: Let patients make their own CAR-T in vivo: https://endpts.com/mpm-backs-53m-round-for-a-bold-concept-let-patients-make-their-own-car-t-in-vivo/

Pulmonary Fibrosis News - https://pulmonaryfibrosisnews.com/2020/11/16/new-targeted-therapies-may-ease-pulmonary-fibrosis-studies-find/

Purdue News: Venture capitalists, Purdue innovations, startups establish winning combination for moving life-changing technologies to public

 

2018

Purdue startup Endocyte sold in $2.1B deal with pharmaceutical giant Novartis

$2.1B Endocyte Deal a Record-Breaker

Indiana life sciences firms raise record $111M in venture capital in 2017

 

2017

Purdue-based biotech company aims to treat cancer by making cancer cells appear to glow

Desi scientist in US discovers molecule that illuminates cancer cells

 

2016

Purdue research may expand engineered T-cell cancer treatment

Research could expand engineered T-cell cancer treatment

 

2014

On Target Laboratories begins Phase 2 clinical trials for its cancer imaging agent

New technology could 'light up' cancer cells and improve surgical outcomes

Purdue University discovery leads to Endocyte drug

 

Videos